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A B S T R A C T
Purpose: Data about super-refractory status epilepticus (SRSE) are scarce. This study aimed to assess the
clinical features and outcome of patients with SRSE.
Method: Clinical features of all SRSE patients admitted to the Neurologic Intensive Care Unit (NICU)/
Neurology Department of West China Hospital, Sichuan University, between January 2010 and August
2013, were retrospectively analyzed. Outcome at discharge, at the three-month and long-term follow-
ups were evaluated using the Glasgow Outcome Scale (GOS). Possible predictors of mortality and
outcome were also evaluated.
Results: Thirteen patients with SRSE were included. Young patients with encephalitis accounted for the
majority of the series (61.5%). In-hospital mortality was 15.4% (2/13), and the three-month mortality was
36.4% (4/11; two patients ceasing therapy were excluded). At the long-term follow-up, 18.2% of patients
improved and 45.5% of patients recovered. Patients of older age and those with multiple complications
had higher mortality compared with those of younger age and those with fewer complications. For
survivors, functional outcome had signiﬁcantly improved at three-month follow-up (GOS
score = 4.1  1.2) compared to that at discharge (GOS score = 3.1  1.2, P < 0.05). Long duration of
anesthesia, etiology of encephalitis and positive neuroimaging ﬁndings tended to be associated with poor
functional outcome.
Conclusion: We conclude that the typical patient susceptible to development of SRSE in West China is a
young patient with encephalitis. Older age and multiple complications increase the risk of death. Most
patients can survive with aggressive therapy, and their functional outcome improves over time.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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Refractory status epilepticus (RSE) is a life-threatening emer-
gency occurring in approximately 10–40% of presentations
with status epilepticus (SE). It is associated with high mortality
(23–39%).1–3 A new deﬁnition has been proposed for ‘‘super-
refractory status epilepticus’’ (SRSE) by Shorvon and Ferlisi, as
‘‘status epilepticus that continues for 24 h or more after the onset
of anesthesia, including those cases in which the status epilepticus
recurs on the reduction or withdrawal of anesthesia’’.4 Data about
the clinical features and outcomes of the SRSE subcategory are
scarce, although RSE has been studied extensively. Randomized* Corresponding author at: Department of Neurology, West China Hospital,
Sichuan University, No. 37 Guoxue Road, Chengdu, Sichuan Province, 610041,
China. Tel.: +86 28 85422549; fax: +86 028 85422893.
E-mail address: zhoudong66@yahoo.de (D. Zhou).
1 These authors contributed equally to this work.
http://dx.doi.org/10.1016/j.seizure.2014.05.014
1059-1311/ 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights recontrolled studies for the treatment of SRSE are not available. Thus,
retrospective analysis is important for research regarding the
management and prognosis of SRSE.
In this study, we reviewed patients with SRSE who were
admitted to the Neurologic Intensive Care Unit (NICU) or
Neurology Department of West China Hospital, Sichuan University.
We aimed to assess the clinical features, management, outcome at
discharge and follow-up, as well as the possible predictors of
mortality and outcome.
2. Patients and methods
2.1. Deﬁnitions
Status epilepticus (SE): We adopted the deﬁnition of SE
proposed by Lowenstein et al.5: SE is deﬁned by clinical and
electrophysiological epileptic activity that lasts for more than
5 min or recurrent epileptic activity without recovery of the pre-
existing level of consciousness over a period of 5 min.served.
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continues despite appropriate anticonvulsant treatment with
benzodiazepines, phenobarbital, or valproate for up to 2 h, usually
requiring general anesthesia.4
Super-refractory status epilepticus (SRSE) is deﬁned as SE that
continues for 24 h or more after the onset of anesthesia, including
those cases in which SE recurs on the reduction or withdrawal of
anesthesia.4
Pre-existing epilepsy: Holtkamp et al.3 proposed that pre-
existing epilepsy is deﬁned as two or more unprovoked epileptic
seizures that occurred more than 4 weeks before the onset of SE.
Post-status epilepticus symptomatic epilepsy: This condition is
established in patients without pre-existing epilepsy, with the
occurrence of at least one unprovoked epileptic seizure occurring
not earlier than 4 weeks after termination of SE.3
Encephalitis: Encephalitis is deﬁned as encephalopathy (de-
pressed or altered level of consciousness lasting for over 24 h, with
mental and behavioral abnormalities), and one or more of the
following clinical or diagnostic ﬁndings: fever, focal neurologic
ﬁndings, seizures, cerebrospinal ﬂuid (CSF) alteration, electroen-
cephalographic (EEG) abnormality, or neuroimaging alteration,
excluding systematic autoimmune disorders, metabolic encepha-
lopathy, and intoxication by screening tests.6
2.2. Patients and clinical data
Consecutive cases of SRSE patients aged 16 years or older, who
were admitted to the NICU or Neurology Department of West China
Hospital, Sichuan University, between January 2010 and August
2013, were retrospectively included for this study. The NICU and the
Epilepsy Center in West China Hospital are the largest centers in
West China. The study was approved by the local ethics committee
of the West China Hospital, Sichuan University. Informed consent
was obtained from each patient or the legal guardians.
Data were retrospectively collated with a structured data
collection table by reviewing the medical charts. Demographic
data (age and sex), clinical features including seizure type, main
tests and examinations, past history and etiology, management of
SRSE, duration of anesthesia, length of stay in the NICU and in the
hospital, and development of post-SE symptomatic epilepsy were
analyzed. Outcome at discharge, at three-month and long-term
follow-ups were analyzed and evaluated by the Glasgow Outcome
Scale (GOS) following Legriel’s study,7 which were categorized
as died (GOS score = 1), not improved (GOS score = 2), improved
(GOS score = 3–4), and recovered to the baseline condition (GOS
score = 5). For patients who lost to follow-up, outcome evaluated
at the last evaluation on clinical outcome was taken for further
analysis.
2.3. Statistical analysis
Statistical analysis was performed with SPSS (version 16.0).
Descriptive summaries were reported as the median (range) or
mean  SD for continuous variables and as frequency for categorical
variables. The Wilcoxon signed-rank test was used for paired
comparison of two time-point outcomes, and Fisher’s exact test was
used for categorical variables, accounting for the relative small sample
size. All tests were two-sided, and the signiﬁcance was set at P < 0.05.
3. Results
3.1. Clinical features
3.1.1. Demographic data and etiologies
Thirteen patients fulﬁlled the diagnostic criteria for SRSE were
included. Eight of the thirteen patients (61.5%) were males.Nine of the thirteen (69.2%) were diagnosed with encephalitis,
two (15.4%) with pre-existing epilepsy without appropriate
antiepileptic therapy, one (7.7%) with stroke sequelae and one
(7.7%) with hypoxic encephalopathy combined with metabolic
acidosis.
The median age of the encephalitis subgroup was 23 years
(range 16–60), while the age of the four patients with other
etiologies ranged from 60 to 81 years. Young patients with
encephalitis were the largest subgroup (8 patients, 61.5% of the
whole SRSE patient group).
3.1.2. Clinical manifestations
In the subgroup of patients with encephalitis, the main clinical
manifestations were fever, altered level of consciousness, mental
and behavioral abnormalities, focal neurologic deﬁcits and
seizures. In terms of seizure type, nine patients initially displayed
intermittent generalized-convulsive seizures (GCS), with the
frequency and duration of seizures gradually increasing until SE
ﬁnally became established. Two patients developed generalized
convulsive SE (GCSE) at the time of onset, and two patients initially
presented with GCS followed by subtle SE. Four patients had
complex partial SE (CPSE) and one patient myoclonus SE.
In the pre-existing epilepsy subgroup, one patient had
two separate seizures (six and three months prior) without
anti-epileptic treatment until the SE incident. Another patient
took antiepileptic drugs (AEDs) irregularly. The patient with a
stroke history presented with new onset refractory status
epilepticus (NORSE). The patient with encephalopathy had
severe pulmonary infections (bacteria and fungi) eliciting
respiratory failure and secondary metabolic acidosis that may
have triggered SE.
3.1.3. Tests and examinations
Continuous video-EEG monitoring was initiated while patients
were in coma, or during the titration or tapering process of
anesthetic agents with the goal of achieving cessation of
electrographic seizures or burst suppression. All patients under-
went neuroimaging involving CT or MRI, systematic immunologic
antibody tests, such as anti-nuclear antibody spectrum (ANAs) and
anti-neutrophil cytoplasmic antibodies (ANCA), thyroid hormone
tests and oncological assessments i.e., serological tumor markers,
thoracic and abdominal tumor screening by imaging investiga-
tions. All patients who were suspected to have encephalitis
received a CSF test and serologic test of immunoglobin-M (IgM)
against Toxoplasma, Rubella, Cytomegalovirus, and Herpes simplex
virus (abbreviated as TORCH). Moreover, from October 2011,
antibodies for the N-methyl-D-aspartate receptor (NMDAR) in the
CSF and serum were tested in patients with suspected anti-NMDAR
encephalitis.
Among the nine patients diagnosed with encephalitis, neuro-
imaging examinations showed abnormalities in two patients on
admission, in three further patients imaging was normal at
admission but turned abnormal when rechecked during the
treatment. Four patients had no abnormal features relevant to
encephalitis on brain imaging. CSF tests revealed mild pleocytosis
in ﬁve patients, mild protein increase in one, intracranial
hypertension in two and no abnormality in one for whom the
lumbar puncture was not rechecked because of contraindications.
A causative agent was identiﬁed in two of the nine patients (22.2%)
with encephalitis (one was Toxoplasma-IgM, the other cytomega-
lovirus-IgM positive). The NMDAR antibodies in the CSF and serum
were tested for one patient, a young female who presented with
psychosis, unresponsiveness and seizures. However, the results
were negative. In addition, all patients had negative systematic
immunologic antibody tests, thyroid hormone tests and oncol-
ogical assessments. None of the patients showed extreme delta
Table 1
Clinical features of the SRSE patients.
Patient no./
sex/age,
years
Seizure
type
Main tests and examinations Main
complications
Past
history
Etiology
Neuroimaginga CSF Serology (TORCH)
1/M/60 GCSE, CPSE Malacia in left
frontal lobe
– – P BT (7 y). EP (2 y) Preexisting EP
2/M/21 GCSE Normal Pleocytosisb Normal P Encephalitis
3/F/16 GCSE Normal/enhanced
in occipital lobe
IH Normal P Encephalitis
4/F/81 GCSE, CPSE Malacia in left
frontal lobe
– – P, ED Stroke (5 y) Stroke sequelae
5/M/19 GCSE Normal/cerebral
edema/normal
Pleocytosis, IH Normal P, hypotension Encephalitis
6/M/23 GCSE, CPSE Bilateral multiple
lesions
IH Tox-IgM (+) P, UTI,
myoglobinuria
Encephalitis
7/F/20 GCSE, CPSE Normal Pleocytosisc, IH Normalc P, UTI Encephalitis
8/M/71 GCSE (onset) Lacunar infarct – – P, UTI, IS, DVI,
Hypo-P, ED, DU
EP (6 m), CRF,
Paraplegia
Preexisting EP
9/M/27 GCSE Normal/cerebral
edema/bilateral
multiple patchy low
density
Pleocytosis, IH Normal P, UTI, HFI, sepsis Encephalitis
10/F/23 Subtle SE Cortical non-
uniform enhanced/
sulci blurred,
ventricle mild
dilated
Normalb,d CMV-IgM (+) P, DVI, Hypo-P,
IS, DU
Encephalitis
11/M/61 GCSE (onset) Normal – – P, PFI, MA,
Hypo-P, ED
RA, SPF, DM Encephalopathy
12/M/29 GCSE,
myoclonus SE
Normal Protein increasedb Normal P, Hypo-P Hypo-T,
psychosis
Encephalitis
13/F/60 Subtle SE Lacunar infarct Pleocytosis, protein increasedb Normal P, ED, Hypo-P Hypertension Encephalitis
Abbreviations: BT, brain trauma; CMV, cytomegalovirus; CPSE, complex partial status epilepticus; CRF, chronic renal failure; CSF, cerebrospinal ﬂuid; DU, decubitus ulcer;
DVT, deep vein thrombosis; ED, electrolyte disturbance; EP, epilepsy; GCSE, generalized convulsive status epilepticus; HFI, hepatic function impaired; Hypo-P,
hypoproteinemia; Hypo-T, hypothyroidism; IgM, immunoglobin-M; IH, intracranial hypertension; IS, infectious shock; MA, metabolic acidosis; P, pneumonia; PFI,
Pulmonary fungal infection; Tox, Toxoplasma; TORCH: Toxoplasma, rubella, cytomegalovirus, and herpes simplex virus; RA, rheumatoid arthritis; SPF, secondary pulmonary
ﬁbrosis; UTI, urinary tract infection; m, month; y, year.
a Neuroimaging ﬁndings revealed a concise summary of MRI (or CT, if no MRI was performed) completed at the early stage of disease and rechecked during the treatment.
b CSF was tested in another hospital or in the emergency department.
c Anti-NMDAR antibody tests of the CSF and serum were negative.
d Lumbar puncture was not rechecked in our department because of contraindications.
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with anti-NMDAR encephalitis.8
3.1.4. Complications
All patients had medical complications during hospitalization.
All thirteen patients had pneumonia, ﬁve had hypoproteinemia,
four had urinary tract infection, four had electrolyte disturbance,
two had deep-veinous thrombosis, two had infectious shock, two
had decubitus ulcer, one had metabolic acidosis, one had hepatic
function impairment, one had sepsis, one had myoglobinuria, one
had hypotension and one had pulmonary fungal infection.
Detailed information for each patient is listed in Table 1
3.2. Management of SRSE
Management of SRSE was mainly conducted in accordance to
the guidelines for SE (2012) and other literatures for RSE.4,9–11
Continuous intravenous anesthetic agents, including midazolam,
diazepam and propofol, were administered either combined or
alone. The anesthetics were tapered after the clinical seizure or
electrographic seizure had been controlled for 24–48 h, and re-
established if recurred.4 The duration of anesthetic cycles
increased gradually over time up to several days, and the weaning
speed slowed down. The dosages of anesthetics were usually
modulated based on clinical seizure activity or EEG-monitoring
ﬁndings and anesthetic complications, most often hypotension or
cardio-respiratory depression. AEDs including valproate, pheno-
barbital, levetiracetam, topiramate, carbamazepine, oxcarbaze-
pine, clonazepam and phenytoin, were administered individuallyin different combinations (range 2–5 categories). Immunologic
therapy including steroids or immunoglobulin and hypothermia
were applied to patients without contraindications. Other treat-
ments like antiviral agents for encephalitis, intracranial pressure
reduction, and symptomatic treatment were applied for complica-
tions. Adjuvant interventions included continuous monitoring of
vital signs, endotracheal intubation or tracheotomy, if necessary,
and mechanical ventilation (data not shown). Detailed data are
shown in Table 2.
3.3. Outcome
3.3.1. Outcome at discharge
Two patients (15.4%) died in the hospital (GOS score = 1),
whereas 11 patients (84.6%) were discharged. Thus, seven patients
needed further therapy (GOS score = 2) and 4 patients could return
home with oral AEDs (GOS score = 3–5). The data about distribu-
tion of GOS outcomes are show in Fig. 1
The mortality in older patients (60 yrs, 3/5, 60%) and patients
with multiple complications (3 types, 4/6, 66.7%) was higher
compared with younger patients (<60 yrs, 1/6, 16.7%) and patients
with less complications (<3 types, 0/5, 0%). However, these
differences were not signiﬁcant (both P > 0.05). The mortality was
not affected by recognition of the etiology of encephalitis (odds
ratio = 0.4, P = 0.576). The mean GOS score for survivors was
2.7  1.1 at discharge. The median anesthetic duration was 5 d (range
1–45 d). The median lengths of stay in the NICU and in the hospital
were 16 d (range 2–45 d) and 25 d (range 2–54 d), respectively.
Detailed data are shown in Table 3.
Table 2
Main therapies for SRSE.
Patient no. Anesthetic, days AEDs (common total dosage per day, gram) Other main therapies for SRSE
1 Dia, 2 VPA(0.8), PB(0.3)
2 Mid + Pro, 2/Dia, 3 VPA(2), PB(0.3), CBZ(0.6) Hypothermia
3 Mid + Pro, 6/Pro + Dia 12 VPA(0.6), PB(0.3), CBZ(0.3), PHT(0.3) Hypothermia
4 Dia, 1 VPA(0.5), PB(0.3), LEV(1), TPM(0.05)
5 Pro + Dia, 9 LEV(1), OXC(0.6)
6 Mid + Pro, 13/Pro, 15 VPA(1.2), PB(0.6), LEV(2), TPM(0.1), CNP(0.004) Steroid, immunoglobulin
7 Dia, 1 VPA(0.6), TPM(0.1), OXC(0.9) Steroid
8 Mid, 3/Pro, 3 VPA(1.2), LEV(1), TPM(0.1)
9 Mid + Pro, 16/Dia + Pro, 29 VPA(1.4), PB(0.3), LEV(3), TPM(0.2), OXC(0.9) Hypothermia, steroid
10 Mid + Pro, 6 VPA(0.8), PB(0.3), LEV(1), TPM(0.1)
11 Mid + Pro, 2 VPA(0.6), PB(0.3)
12 Dia, 1/Dia + Pro, 1/Mid, 2 VPA(1), LEV(1.5), TPM(0.05), CNP(0.002) Hypothermia
13 Pro, 2/Mid, 3 VPA(0.8), PB(0.2), LEV(1), TPM(0.1)
Abbreviations: AEDs, anti-epileptic drugs; CBZ, carbamazepine; CNP, clonazepam; Dia, diazepam; LEV, levetiracetam; Mid, midazolam; OXC, oxcarbazepine; PB,
phenobarbital; PHT, phenytoin; Pro, propofol; TPM, topiramate; VPA, valproate.
Table 3
Outcome at discharge and three-month and long-term follow-ups for each SRSE patient.
Patient no. Duration of
anesthesia, d
Length of stay, d Outcome at discharge GOS score
at discharge
GOS score at
three-month
follow-up
GOS score at
long-term
follow-up
Post-SE
symptomatic
epilepsy
In NICU In hospital
1 2 – 7 Seizure controlled 5 5a 5a
2 5 5 5 Seizure relapse 2 1b
3 18 21 21 Seizure relapse 2 1b
4 1 – 27 Seizure controlled 3 5 5 No
5 9 16 31 Seizure controlled 4 5 5 Yes. Free for 25 m
6 28 44 54 Seizure cessation but in coma 2 2 3 Yes. Free for 12 m
7 1 15 24 Seizure relapse 2 4 5 No
8 6 38 43 Seizure cessation but in coma 2 1c
9 45 45 47 Seizure relapse 2 3 4 Yes. Recurrent
10 6 6 6 Died 1d
11 2 2 2 Died 1e
12 4 7 25 Seizure controlled 4 5 5 No
13 5 25 25 Seizure cessation but in lethargy 2 1c
Abbreviations: GOS, Glasgow Outcome Scale; NICU, neurologic intensive care unit; SE, status epilepticus; d, day; m, month.
a The patient was lost to follow-up, so the last evaluation of clinical outcome was taken for analysis.
b The patient gave up therapy and died 24 h after discharge.
c The patient was seizure controlled and awake but later died of systematic complications.
d The patient had a long course of consciousness disorder and recurrent seizures before this episode of SE, combined with severe systematic complication; she died of
central respiratory and circulatory failure.
e The patient died of multi-organ failure.
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After being discharged from the hospital, two patients with
seizure relapse died 24 h after ceasing therapy, whereas ﬁve
patients continued to receive treatment in a local hospital forFig. 1. Overall outcome at discharge, at three-month and long-term follow-ups. GOS scor
recovered to the baseline condition; GOS, Glasgow Outcome Scale.weeks or months. At the three-month follow-up, two patients
(seizure cessation; 60 yrs) died because of fatal systematic
complications. For the seven patients who survived until the time
of follow-up, the mean GOS score signiﬁcantly increased frome = 1: died; GOS score = 2: not improved, GOS score = 3–4: improved, GOS score = 5:
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(P = 0.038).
At the three-month follow-up, a higher proportion of patients
requiring a longer period of anesthesia (2/3 with >4 d, versus 1/4
with 4 d) and a higher proportion of those with encephalitis (3/5
versus 0/2 of non-encephalitis) had not fully recovered (GOS
score = 2 to 4). Nonetheless, the differences were not signiﬁcant
(both P > 0.05). Moreover, among the six survivors without pre-
existing epilepsy, three patients (50%) developed post-SE symp-
tomatic epilepsy.
At the long-term follow-up (median 17 months, range ﬁve
months to 44 months), the mean GOS score was 4.6  0.8 versus
4.1  1.2 at three-month follow-up (P = 0.083).
Similarly, at the long-term follow-up, there was higher
proportion of patients who had required longer anesthesia (2/3,
with >4 d, versus 0/4, with 4 d) or who had experienced
encephalitis (2/5 versus 0/2 of non-encephalitis patients) had
not fully recovered. The differences were still not signiﬁcant (both
P > 0.05). Moreover, at long-term follow-up, the two patients with
positive neuroimaging ﬁndings had poorer functional outcome
with a GOS score of 3 or 4, compared with other ﬁve patients all
with GOS score of 5.
The detailed data are presented in Table 3 and Fig. 1.
4. Discussion
Encephalitis is the most common etiology (69.2%) in the present
13 SRSE patients from West China, but it accounted for a lower
proportion of the RSE (22.2%) and non-refractory SE (NRSE; 4.3%)
than in a previous study.3 Other etiologies included pre-existing
epilepsy without appropriate antiepileptic treatment, stroke
sequelae and encephalopathy. In this series of SRSE, encephalitis
was the primary cause and mainly occurred in young patients,
which is consistent with the study of Holtkamp about malignant SE
(deﬁned as recurring SE within 5 d after tapering of anesthetic).12
Pre-existing epilepsy is a minor entity that is primarily associated
with NRSE.3
As proposed by the California Encephalitis Project (CEP), the
deﬁnition of encephalitis includes infectious, noninfectious,
and unknown etiologies. The relationship between encephalitis
and identiﬁed pathogen is ranked into conﬁrmed, probable, and
possible causes.6 In our series, nine patients were clinically
diagnosed with encephalitis, among whom only two patients
(22.2%) were identiﬁed with a possible infectious etiology.
Nevertheless, anti-NMDAR encephalitis, which has been reported
to surpass the viral etiologies,13 was not observed based on clinical
signs, symptoms, and ancillary tests. The ﬁndings from epidemio-
logical studies suggested that the majority of cases are still of
unknown etiology.6,14
The present study indicated the in-hospital mortality was
15.4%, and the three-month mortality was 36.4% (except for two
patients who gave up therapy). These ﬁndings indicate that older
patients (60 yrs) and patients with multiple complications tend
to have a higher risk of death, whereas an etiology of encephalitis
has no effect on mortality. A recent review identiﬁed age and
etiology as the principal independent outcome predictors of RSE.11
However, the choice of anesthetic agents is independent of
mortality.2,15 No comparative study about the appropriate AED
regimens and optimal immunotherapy is currently available.4
Eleven patients were discharged from the hospital with a long
period of stay in the NICU or in the hospital. Seven of these 11
patients at discharge were in critical condition with seizure
recurrence or consciousness disorder. Patients with prolonged RSE
were more severely disabled than those with RSE at hospital
discharge.12 Pneumonia was the ﬁrst prevalent complication in
this series. A previous study indicated that pneumonia andprolonged mechanical ventilation are related to poor outcomes
in RSE.16
At long-term follow-up, two patients improved but still had
neurologic deﬁcits (18.2%), while 5 patients recovered to baseline
condition (45.5%). We observed that a longer duration of needed
anesthesia, etiology of encephalitis, and positive neuroimaging
ﬁndings may result in a tendency of more severe neurologic
sequelae, but the deﬁcit gradually ameliorated over time. Due to
the small number of patients, we cannot state with certainty
whether these factors can affect the outcome of SRSE. A prior study
on RSE also supported that longer duration of anesthesia required
to achieve control of SE signiﬁes worse functional outcome.16 A
study of prolonged SE supported that surviving patients have poor
functional outcome at hospital discharge but return to good
cognitive and functional status over time.17 Another report
suggested the use of aggressive therapy in prolonged RSE if an
MRI remained normal.18 The long-term outcome of this series
(45.5% recovered) is more favorable than the review of outcomes in
RSE and SRSE (35% recovered) by Shorvon and Ferlisi.19 Therefore,
we recommend the continuation of aggressive anesthesia and
support treatment in young patients without fatal systematic
complications, particularly without responsible lesions on neuro-
imaging ﬁndings.
In our study, 50% of survivors developed symptomatic epilepsy
post-SE. In a cohort study, symptomatic epilepsy developed in
signiﬁcantly more RSE patients (87.5%) than non-refractory SE
patients (22.2%).3 The current study probably underestimated the
frequency because of the shorter follow-up and limited number of
patients. However, it is still controversial that symptomatic
epilepsy develops due to SE itself or underlying etiology.
This report is limited by the small number of patients, a
retrospective and descriptive study design, which did not allow the
drawing of ﬁrm conclusions about the possible predictors of SRSE
and clinical outcome. Another limitation is the insufﬁciency of the
detection methods. The causative agents were not tested by agent-
speciﬁc PCR or cultured pathogens, and NMDAR antibodies were
tested in one patient only who was suspected to have autoimmune
encephalitis. The other eight patients were clinically ruled out of
having autoimmune encephalitis because of the absence of typical
clinical and epidemiological features. For instance, anti-NMDAR
encephalitis is more common in young adult females and is
characterized by psychosis, decreased consciousness, seizures,
language dysfunction, dyskinesia and a unique EEG pattern of
EDB.8,13,20
To our knowledge, this study is the ﬁrst series report based on
the deﬁnition of SRSE with regard to the clinical features,
management, and outcome of SRSE in China. In further studies,
we will exert more efforts to establish a database in China
regarding the clinical features and outcome of patients with SRSE,
which will then estimate the therapeutic regimen, predictors on
outcome, and possible impacts of SRSE.
5. Conclusion
Our results indicate that encephalitis is the primary cause of
SRSE in West Chinese adults, and the typical patient susceptible to
develop SRSE is young patient with encephalitis. The factors of old
age and multiple complications tend to increase the risk of death.
Most patients can survive with aggressive therapy. For young SRSE
patients, survival with a meaningful functional recovery over a
long duration is possible.
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